AZ Joins Spin-Out Set, Forms GI Play Albireo
This article was originally published in Start Up
Executive Summary
AstraZeneca has completed its first ever biotech spin out, creating the Swedish biotech firm Albireo with backing led by Nomura Phase4 Ventures. The deal underscores pharma's disenchantment with certain aspects of GI drug development and may blaze a trail for other non-core areas of R&D at the drugmaker.